Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BPM31510
- Development stage
- Phase 2
- Lead developer
- Berg
- Modality
- Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous, Topical
01
Overview
BPM31510 is a lipid-drug conjugate nanodispersion specifically formulated to deliver supraphysiological concentrations of ubidecarenone (oxidized coenzyme Q10, also known as CoQ10) to target cancer cell metabolism. By shifting tumor bioenergetics from glycolytic (lactate-dependent) pathways toward mitochondrial oxidative phosphorylation (OxPhos), BPM31510 increases mitochondrial reactive oxygen species (ROS) production in tumor cells, leading to apoptosis. This mechanism exploits the metabolic vulnerabilities of cancer cells while sparing normal tissues. BPM31510 has been investigated in both intravenous and topical formulations for various indications including advanced pancreatic cancer, high-grade glioma/glioblastoma multiforme, and epidermolysis bullosa. The drug has demonstrated potential as a chemotherapy and radiation sensitizer with manageable side effects[1][2][3][6][8].
- Other names
- ubidecarenone-lipid conjugate nanodispersionCoQ10 nanodispersionCoQ-10 nanodispersionCoQ 10 nanodispersionubidecarenone injectable nanosuspension
02
Targets
ND1 (Mitochondrial electron transport chain complex I)
Beyond the preview
Go deeper on BPM31510.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BPM31510.